3456466
Last Update Posted: 2018-03-07
Recruiting status is unknown
All Genders accepted | 18 Years-75 Years |
122 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma
Primary Outcome Measures:
Area under the curve (AUC) forTQB2303 and rituximab concentrations [ Time Frame: 85 days ]
Secondary Outcome Measures:
The Maximum Concentration (Cmax) of the TQB2303 and rituximab [ Time Frame: 85 days ] The area under the plasma concentration-time curve from 0 to inf (infinite) time (AUC0-∞); The time to reach the maximum plasma concentration after treatment (Tmax) Total clearance (CL); Elimination of half-life (t1 / 2); Apparent distribution volume (Vd).
Eligibility
Relevant conditions:
Non-hodgkin's Lymphoma
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov